Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study evaluating the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan

Next Previous
X
Search
Trial Profile

Phase 1 study evaluating the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efzofitimod (Primary)
  • Indications Interstitial lung diseases
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Kyorin Pharmaceutical

    • Most Recent Events

    • 10 Aug 2021 Status changed from recruiting to completed as per aTyr Pharma media release
    • 19 Jan 2021 According to an aTyr Pharma media release, last subject visit has been completed in the trial. Results from this study are intended to enable Kyorin to initiate patient trials in interstitial lung disease (ILD) in Japan.
    • 12 Nov 2020 According to an aTyr Pharma media release, the company has initiated and continues to enroll patients in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top